perigirlies Get my score

What helps

HRT for perimenopause: what it fixes, and what it doesn't

Hormone therapy is the most effective treatment there is for hot flashes and night sweats. That sentence sits at the top of every current guideline, and it is worth saying without hedging, because most of the internet hedges it. The same documents are just as blunt about the things it does not fix. Both halves are on this page, and every number has the document it came from sitting next to it.

Free. No email required. No signup required. Takes about 2 minutes. Scored entirely in your browser: your answers are never stored or sent anywhere. Your score is shown next to the average for your age band.

Four control dials in a row. The first has been turned right down and its marker is coral; the other three sit where they were.

What it actually fixes

Pooled against placebo, oestrogen alone or oestrogen with a progestogen cut weekly vasomotor episodes by 75%, with a confidence interval running from 64 to 82, and produced an odds ratio of 0.13 for symptom severity. The statement that reports those numbers adds that no other pharmacologic or alternative therapy tested has provided more relief.1 That is the strongest single claim on this whole site, and it is the reason this page exists.

  • Hot flashes and night sweatsThis is the headline indication and the one the evidence is built on. It is also the outcome almost every trial in the field chose to measure, which matters later on this page.
  • Genitourinary symptomsDryness, burning, pain with sex, recurrent urinary infections. Systemic therapy treats these, but when they are the only complaint the guidance prefers low dose vaginal oestrogen instead: same hormone, a fraction of the dose, minimal absorption into the bloodstream.5
  • Bone loss and fracturePrevention of both is an established effect rather than a hoped-for side benefit, and it is part of why the benefit and risk arithmetic changes with age.1
  • Sleep, partly and often second handA review of 23 studies found 14 with positive results for chronic insomnia in menopausal women, and there is some evidence that transdermal oestrogen benefits sleep in perimenopausal women independently of hot flashes. If you stop waking up drenched, you sleep better; some of the effect is that simple.1

There is a window attached to all of it. For women under 60, or within ten years of their final period, and with no contraindications, the benefit and risk balance is described as favourable for treating bothersome vasomotor symptoms and preventing bone loss. Start more than ten years out, or after 60, and the same statement says the balance looks less favourable, because the absolute risks of coronary heart disease, stroke, clots and dementia are higher by then.1

What it does not fix

This is the part that gets left off the landing pages, and it is not a matter of interpretation. The first three below are Level I key points in the current hormone therapy position statement, meaning good and consistent scientific evidence, and every one of them is a negative finding.1 The fourth is more complicated, and the complication turns out to be specific to this stage.

  • Memory and brain fogIn the absence of more definitive findings, hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia. That opening hedge is the document's own, and it is doing work: three large trials found neutral effects on cognition when therapy was started early after menopause, while small trials do support oestrogen for cognition when it is started immediately after surgery that removes both ovaries. Neither of those is brain fog in perimenopause, which is the question most people are actually asking. And none of it says nobody's head clears: sleeping through the night changes how a brain performs, and plenty of people notice.
  • Bladder leakingSystemic hormone therapy does not improve urinary incontinence and may increase stress incontinence, and it carries no FDA approval for any urinary health indication. Low dose vaginal oestrogen is the one with evidence behind it here, including for recurrent urinary tract infections and urgency.
  • Libido, arousal and orgasmSystemic therapy generally does not improve sexual function, sexual interest, arousal or orgasmic response independently of what it does for genitourinary symptoms. If sex hurts, treating the tissue helps. If desire has gone and nothing hurts, this is not the lever.
  • Depression that meets diagnostic criteriaThe mood evidence is Level II, weaker than the rest, and it is oddly specific to this stage: there is some evidence that oestrogen therapy has antidepressant effects of a similar size to antidepressants when given to depressed perimenopausal women, while being ineffective for depressive disorders after menopause. Oestrogen carries no government approval to treat mood disturbance.1

I had this expectation of the HRT alone making me feel like a million bucks, but I think its purpose is to just keep us status quo.

r/Perimenopause, 176 upvotes

That comment is doing something the marketing never does, which is setting a floor instead of a ceiling. A treatment can be the best one available and still not be the thing that hands your old life back.

Both halves of this page in one view. The word on each bar is our reading of the finding and not the statement's own vocabulary: what the document assigns is the Level named beside each bar, and Level I sits behind the top three and the bottom two alike. The length of the bar is our reading of it too, and it is the weight of the evidence rather than the size of the effect. The bottom two are negative findings rather than missing ones, and they are not the same negative: systemic therapy generally does not improve desire or arousal apart from what it does for the tissue, while for cognition the recommendation is a not recommended that the document hedges itself, as the memory bullet above sets out.1

Why perimenopause is the harder case

Nearly everything above was settled in women who had already finished. Perimenopause is a moving target, and the guidance says so out loud: data are insufficient on the risk attached to long term hormone therapy use in perimenopausal women, and in postmenopausal women under 50.1 That is a gap in the evidence, not a warning, and it is the honest reason a clinician may want to review a perimenopausal prescription more often than a postmenopausal one.

The second complication is that your own hormones are still moving. Frequent vasomotor symptoms are one of the two things the guideline uses to identify perimenopause in the first place, alongside a change in your cycle, and a cycle that is still changing means a background that is still changing underneath any dose.4 There is more on why one blood test cannot capture that in what a perimenopause test can and cannot tell you.

The third is the one nobody raises until it is awkward. NICE tells clinicians to share information about contraception with anyone who has menopause-associated symptoms, and points them at separate guidance written for people over 40.4 Symptom relief and contraception are two different conversations, and if only one of them happens at your appointment, it is usually the first.

Nothing here is a recommendation about your treatment. It is a description of what the current guidance says, so that you recognise the options when someone offers them and notice when something is missing.

The risk, in numbers you can hold

The breast cancer question is the one that empties the room, and it is usually answered in relative risk, which is the format most likely to frighten and least likely to inform. Here it is in absolute numbers, from the current statement's own key point: the risk is described as rare, at fewer than one additional case per 1,000 women per year of use, or three additional cases per 1,000 women over five years of conjugated equine oestrogens with medroxyprogesterone acetate.1

The same document asks clinicians to put that beside the things nobody counsels anyone about: it places the risk on a par with two alcoholic drinks a day, obesity, and low physical activity.1 Whether that comparison lands as reassuring or as an indictment of how the other three get discussed is up to you.

Risk is not one number, either. It moves with the type of hormone, the dose, how long you take it, the route it goes in by, when you started, and whether a progestogen is involved. A statement that can be summarised in one sentence is a statement that has been flattened.

How long this actually runs

Most people arrive at this decision believing they are managing a phase that lasts a couple of years. The largest study to follow the question found a median total duration of frequent vasomotor symptoms of 7.4 years, and a median of 4.5 years of them continuing after the final period.2

The number that should be on posters is the subgroup one. Among women who were premenopausal or early perimenopausal when they first reported frequent flashes, the median total duration was longer than 11.8 years, with a median 9.4 years of them persisting past the final period.2 If your heat started while you were still cycling, you are in the group with the longest run ahead of it, not the shortest.

Waiting it out is therefore a real choice with a real length attached, and it is worth knowing that the symptom does not peak while you are still bleeding. Vasomotor symptoms increase across the transition and peak roughly one year after the final menstrual period.3 The quiet stretch people expect at the end is usually the loud one.

And stopping is not a clean exit. Vasomotor symptoms return in approximately 50% of women when hormone therapy is discontinued, and there is no consensus on whether stopping abruptly or tapering is better.1 That is worth knowing at the start rather than at the end.

Taking this to an appointment

If you are 45 or over and otherwise healthy, the guideline identifies perimenopause without any laboratory test: recently started vasomotor symptoms plus any change in your menstrual cycle is the whole criterion.4 You do not have to arrive with a blood result, and being told your levels are normal is not an answer to the question you asked.

The instruction on treatment is similarly short. NICE recommendation 1.5.1 reads, in full: offer HRT to people with vasomotor symptoms associated with menopause.4 Not consider. Offer.

If hormones are ruled out for you, or you would rather not, that is not the end of the list. Menopause-specific cognitive behavioural therapy, clinical hypnosis, fezolinetant, gabapentin and several antidepressants all carry a positive recommendation in the current nonhormone statement.6 They are ranked, with what each one is actually for, in what actually helps perimenopause.

Common questions

Does HRT work for perimenopause, or only after menopause?

The evidence for vasomotor symptoms covers the transition as well as postmenopause, and UK guidance says to offer HRT to people with vasomotor symptoms associated with menopause without waiting for periods to stop. What is thinner is the long term safety data specifically in perimenopausal women, which the current hormone therapy statement describes as insufficient. That is a reason for regular review, not a reason to wait.

How much does HRT reduce hot flashes?

Pooled against placebo, oestrogen alone or oestrogen with a progestogen reduced weekly vasomotor episodes by 75%, with a confidence interval from 64 to 82, and produced an odds ratio of 0.13 for symptom severity. The statement reporting those figures adds that no other drug or alternative therapy tested has provided more relief.

Will HRT fix my brain fog?

The current position statement says that in the absence of more definitive findings, hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function or dementia, and it grades that at its strongest level of evidence. Three large trials of therapy started early after menopause found neutral effects on cognition. Many people do report thinking more clearly on it, which is not a contradiction: sleeping through the night changes how a brain performs.

Does HRT help low libido?

Not on its own terms. Systemic hormone therapy generally does not improve sexual function, sexual interest, arousal or orgasmic response independently of its effect on genitourinary symptoms. Where sex has become painful or the tissue has changed, treating that does help, and low dose vaginal oestrogen is the option with the evidence behind it for exactly that.

What is the actual breast cancer risk with HRT?

The current statement puts it at fewer than one additional case per 1,000 women per year of use, or three additional cases per 1,000 women over five years of conjugated equine oestrogens with medroxyprogesterone acetate, and describes that as rare. It asks clinicians to present the risk alongside comparable ones such as two alcoholic drinks a day, obesity and low physical activity. Your own number depends on the type, dose, duration and route, which is a conversation for someone who knows your history.

How long will I need to stay on it?

There is no fixed answer, and the underlying symptoms last longer than most people expect. The median total duration of frequent vasomotor symptoms is 7.4 years, and longer than 11.8 years for women whose symptoms began while they were still cycling. Symptoms return in roughly half of women when hormone therapy is stopped, and there is no consensus on whether tapering beats stopping abruptly.

Do I still need contraception on HRT?

This page cannot answer that for you, and it is a question worth asking directly rather than assuming. NICE tells clinicians to share information about contraception with anyone who has menopause-associated symptoms, and points them at separate guidance written for people over 40. Symptom relief and contraception are two different conversations, and only one of them tends to happen without prompting.

What are the options if HRT is ruled out for me?

A real list, not a consolation prize. The current nonhormone statement recommends menopause-specific cognitive behavioural therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant at its strongest evidence level, and oxybutynin one level below. Several of those do not require a prescription at all.

Keep going

What actually helps perimenopauseEvery option with real evidence behind it, ranked, and the list of what does not hold up. What a perimenopause test can tell youWhy one blood draw cannot capture a hormone level that is still moving. The stages of menopauseEvery STRAW+10 stage, and where perimenopause actually starts and ends. Signs perimenopause is endingCheck which stage you are in, and what is typically left.

Know what you are asking for

The conversation goes better when you arrive with a pattern rather than a list of complaints. Nineteen symptoms across four domains, plus your cycle, scored against the average for your age band and printable for the appointment.

You are allowed to want the thing that works and to know exactly what it will not do.

Take the 2-minute check

Free, no email, no signup. Scored entirely in your browser. Screening, not diagnosis. No provider is linked from this page and nothing on it is sponsored.